Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic intravenous fibrinogen to reduce blood loss during posterior spinal fusion surgery
IRCT20231113060037N3Phase 3Recruiting
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Fibrinogen human (3 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Total intraoperative blood loss, Requirement for perioperative blood transfusion and 1 more. Started Oct 2026; status: recruiting.
02
Drugs
Fibrinogen human
Beyond the preview
Go deeper on IRCT20231113060037N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231113060037N3.